Clinical trials: Sintilimab
Colorectal Cancer, Adult
PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases
In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with anti-programmed cell death -1 (anti-PD1) antibody therapeutic regimen (sintilimab) will be evaluated in patients with advanced…
- Trial name
- NCT07411781
- Testing
- PIN+sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chinese PLA General Hospital
Biliary Tract Cancer
Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer
This is a prospective, single-arm, exploratory interventional study designed to evaluate the efficacy and safety of liposomal irinotecan (II) plus fluorouracil/leucovorin (5-FU/LV) and sintilimab with sequential stereotactic body…
- Trial name
- NCT07797816
- Testing
- Irinotecan Hydrochloride Liposome Injection (II), Fluorouracil, Leucovorin
- Where
- China
- Volunteers
- 31 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NSCLC (Non-small-cell Lung Cancer)
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell lung cancer (NSCLC)
- Trial name
- NCT05118334
- Testing
- Sintilimab, IBI310
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Resectable Non-small Cell Lung Cancer
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
This clinical trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Limertinib Followed by Sintilimab and Chemotherapy in resectable Stage II-IIIB EGFR-Mutant NSCLC.
- Trial name
- NEO-LISI (NCT07038460)
- Testing
- Limertinib+sintilimab+chemotherapy, Limertinib+chemotherapy, surgery
- Where
- 6 sites in China
- Volunteers
- 134 people
- Sponsor
- Wen-zhao ZHONG
DLBCL
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
The purpose of this study is to determine whether treatment with IBI110 single agent and in combination with sintilimab demonstrates sufficient efficacy/safety in r/r DLBCL.
- Trial name
- NCT05039658
- Testing
- IBI110 plus sintilimab, IBI110
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy
the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer
To explore the predictive value of immune cells by single-cell sequencing on the outcome of locally advanced cervical cancer treated by concurrent chemoradiotherapy Followed by PD-1 inhibitor
- Conditions
- Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy, Immunotherapy
- Trial name
- NCT06378840
- Testing
- Nab-paclitaxel/Platinum, Sintilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Small Cell Lung Cancer Limited Stage
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
The study is a prospective, multi-center, open-label, randomized, and controlled phase II clinical trial.
- Trial name
- NCT04189094
- Testing
- Sintilimab, Etoposide, Cisplatin
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Astrocytoma of Brain
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma
This is an ongoing Phase 2, open-label, single-center, non-randomized study of sintilimab (one anti-PD-1 antibody same as nivolumab approved in China) plus bevacizumab administered in a low dosage schedule in adult (≥ 18 years)…
- Trial name
- NCT05518994
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Henan Provincial People's Hospital
Carcinoma, Intrahepatic Cholangiocarcinoma
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
This is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients…
- Conditions
- Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Neoplasms, PD-1 Inhibitor
- Trial name
- NCT05913661
- Testing
- Pemigatinib, PD-1 Inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.
This clinical study is designed as a prospective, open-label, single arm, multicenter study to evaluate the clinical efficacy and safety of Sintilimab and Nimotuzumab in combination with chemotherapy in patients with newly…
- Trial name
- Carpp-1 (NCT04882462)
- Testing
- Nimotuzumab, Sintilimab, Chemotherapy drug
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Locally Advanced Cervical Cancer
Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC
Concurrent chemoradiotherapy -immunotherapy followed by ICI maintenance was proved to improve the PFS by the Keynote-A18 in the LACC patients, and still more than 30% progressed.
- Trial name
- NCT06916117
- Testing
- Neoadjuvant Chemotherapy (NACT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital
Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect
Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study
To evaluate the efficacy and safety of PD-1 immune checkpoint inhibitor combined with bevacizumab in the treatment of metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy.
- Trial name
- NCT04872582
- Testing
- PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- XIANG YANQUN
Non-Small Cell Lung Cancer, Adjuvant Therapy
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
This multicenter, randomized, open-label, phase II trial is designed to evaluate the efficacy and safety of adjuvant sintilimab in patients with completely resected non-small cell lung cancer who remain at high risk of recurrence…
- Conditions
- Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- RICA (NCT07748325)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sichuan University
Metastatic Colorectal Cancer
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
Immune checkpoint inhibitors have a poor effect on MSS colorectal cancer. Studies have shown that SBRT, chemotherapy and anti-vascular therapy can enhance the anti-tumor effect of PD-1 antibody.
- Trial name
- NCT05438108
- Testing
- SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huazhong University of Science and Technology
Small Cell Lung Cancer Extensive Stage
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the…
- Trial name
- NCT04967625
- Testing
- Sintilimab, Anlotinib hydrochloride
- Volunteers
- 23 people
- Sponsor
- Zhejiang Cancer Hospital
Oligometastasis, Lung Neoplasms
Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer
The study aim to investigator the efficacy and safety of sintilimab after Stereotactic Ablation Brachytherapy(SABT) for refractory oligometastatic non-small cell lung cancer(NSCLC), who had failed second-line systemic therapy.
- Trial name
- NCT04486287
- Testing
- Sintilimab
- Volunteers
- 44 people
- Sponsor
- Tianjin Medical University Second Hospital
Gastric Cancer
HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis
To evaluate the Safety and Efficacy of HIPEC Combined With Sintilimab for Gastric Cancer Patients with Peritoneal Metastasis.
- Trial name
- NCT05648487
- Testing
- HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery
- Volunteers
- 46 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Non-small Cell Lung Cancer
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
- Trial name
- ATHENA (NCT04322617)
- Testing
- Anlotinib plus the same Immune Checkpoint Inhibitors., Anlotinib plus the new Immune Checkpoint Inhibitors., Anlotinib
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Hunan Province Tumor Hospital
Relapsed or Refractory Classical Hodgkin's Lymphoma
Intense Monitoring Study on Tyvyt
The study is a multi-center, prospective, non-interventional and observational study, and will collect data on the safety and efficacy of Tyvyt® in the treatment of Chinese patients with relapsed or refractory classical Hodgkin's…
- Trial name
- NCT04237233
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Locally Advanced Head and Neck Squamous Cell Carcinoma
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
The goal of this prospective, randomized, single-blind controlled clinical study is to explore the efficacy of maintenance therapy with Sintilimab after chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.
- Trial name
- NCT06240689
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine